3000+ Attendees, 450 Speakers, 12 Conference Tracks, 100+ Posters
MMTC M Header 

Cambridge Healthtech Institute’s Eleventh Annual 

Translational to Clinical R&D

Strategies and Technologies to Reduce Attrition and Improve Clinical Outcomes

February 15-18, 2015 | Moscone North Convention Center | San Francisco, CA  
Part of the 22nd International Molecular Medicine Tri-Conference 


Despite the many breakthroughs in high-throughput omics, a deeper understanding of disease biology, and increased investments in R&D, productivity in drug development has rapidly declined—with significant losses during transition from phase II to III. Improving efficiency during the early stages of R&D has the potential to accelerate the development of novel medicines for patients in need, while increasing the odds of success during phase II studies, and throughout clinical trials. Yet, how do developers find practical ways to overcome the translational challenges resulting in high rates of attrition from failed clinical trials? What lessons have been learned from retrospective analysis of terminated programs? What are emerging strategies derived from novel science and technologies improving the translation from benchtop to bedside? 

Cambridge Healthtech Institute’s Translational to Clinical R&D is designed to convene thought leaders working in early discovery and development to bring forth emerging strategies to shift POC to earlier, more cost-effective stages, increase R&D efficiency using novel science and technologies, and ultimately to ensure the right drug is developed for the right target and reaches the right patients in need.

Who should attend: Executives, Directors, Principal Investigators, Managers, Research Scienctists from Pharma, Biotechs, Academia, Government and Healthcare Organizations working in fields such as Drug Discovery and Development, Pre-Clinical to Clinical R&D, Genomics, Cell/Molecular/Disease Biology, Diagnostics, Pharmacology, Toxicology and Safety

Topics may include, but are not limited to: 

  • Novel and emerging therapeutic strategies
    • Multi-target drugs 
    • RNA therapeutics  
    • Immunotherapies  
    • Antibody-Drug Conjugates (ADCs)  
  • Strategies for combination therapies
  • Novel biomarkers predictive of response
  • Genomics for drug repositioning
  • Big data omics integration for disease pathways & models
  • Translatable biomarkers and imaging
  • Predictive preclinical models
  • Phenotypic and label-free drug discovery 
  • Disease/physiologically-relevant phenotypic systems
    • Primary, embryonic (ESC) and induced pluripotent (iPSC) stem cells 
    • 2D/3D cell culture systems 
    • Genetically engineered mouse models (GEMMs) 
    • Zebrafish models 
    • Patient-derived xenografts  
  • Predictive in vitro toxicology
    • Organoid models

If you would like to submit a proposal to give a presentation at this meeting, please click here.

The deadline for submission is July 18, 2014. 

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships. 

 For more details on the conference, please contact:
Kip Harry
Conference Director
Cambridge Healthtech Institute
T: (+1) 781-972-5454
E: kharry@healthtech.com 

For partnering and sponsorship information, please contact:
Jon Stroup (Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com 

Joseph Vacca (Companies L-Z) 
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781.972.5431
E: jvacca@healthtech.com 



Premier Sponsors:

Leica Biosystems 





Jackson Laboratory - small logo